Literature DB >> 2651588

The effects of dexamethasone on C6 astrocytoma radiosensitivity.

C D Lordo1, E C Stroude, R F Del Maestro.   

Abstract

Brain-tumor patients often undergo radiation therapy while receiving corticosteroids for the treatment of cerebral edema. Studies have demonstrated that dexamethasone is radioprotective in a number of cell lines. The C6 astrocytoma cell line is well established in vitro and is modulated by dexamethasone treatment. It has therefore been hypothesized that dexamethasone-treated C6 astrocytoma cells would be more resistant to radiation-induced damage. The present study was carried out to assess this hypothesis using both the in vitro C6 astrocytoma monolayer and three-dimensional multicellular spheroid models. Dexamethasone was inhibitory to the C6 astrocytoma cells in the monolayer preparation, increasing their doubling time by 13%. In the spheroid cultures, dexamethasone treatment decreased the number of cells per spheroid by 46%. Dexamethasone did not affect the plating efficiency of either the cells from the monolayer experiment or those dissociated from spheroids, however, suggesting that the inhibitory effect was not tumoricidal. At a clinical concentration (1.94 x 10(-5) M), dexamethasone did not significantly influence plating efficiency of irradiated C6 astrocytoma cells in monolayer or three-dimensional spheroid cultures.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651588     DOI: 10.3171/jns.1989.70.5.0767

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  2 in total

1.  General protease and collagenase (IV) activity in C6 astrocytoma cells, C6 spheroids and implanted C6 spheroids.

Authors:  I S Vaithilingam; E C Stroude; W McDonald; R F Del Maestro
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

2.  Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion.

Authors:  Danny Del Duca; Tamra Werbowetski; Rolando F Del Maestro
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.